
Motor Neurone Disease (Sales) Limited
Annual Report and Financial Statements
for the year ended 31 January 2006

Registered no: 1989172



Motor Neurone Disease (Sales) Limited

Legal and Administrative Details for the year ended 31 January 2006

Directors

A Graham	
A Johnston	
G Marriott	Resigned 17 October 2005
A Horwell	Appointed 17 October 2005

Registered Office

David Niven House
10-15 Notre Dame Mews
Northampton
NN1 2PR

Professional Advisers

Registered Auditors	Sayer Vincent 8 Angel Gate City Road London EC1V 2SJ
Solicitors	Bates, Wells & Braithwaite 2 – 6 Cannon Street London EC4M 6YH
Bankers	Lloyds TSB Bank plc Public and Community Sector 3 rd Floor 25 Gresham Street London EC2V 7HN

Motor Neurone Disease (Sales) Limited

Directors' Report

For the year ended 31 January 2006

The directors present their report and the audited financial statements for the year ended 31 January 2006.

Principal activities

The company engages in sales to raise funds for the Motor Neurone Disease Association.

Review of business and future developments

The results for the year are set out in the profit and loss account on page 6. The result for the year of £5,000 will be transferred to reserves.

Donations of £14,963 were received on behalf of the Motor Neurone Disease Association and are not contained in these accounts. These donations will be paid to the Association during the year ending 31 January 2007.

During the year activities organised on behalf of the Motor Neurone Disease Association raised £32,862 after expenses. The income and expenditure for the activities are included in these accounts. £11,771 of the net income was paid to the Association during the year, and £21,091 will be paid during the year ending 31 January 2007.

Both the level of business and the year end financial position were satisfactory, and the directors expect the current level of activity to be maintained for the foreseeable future.

Dividends

The directors do not recommend the payment of a dividend.

Directors

A list of directors is shown on page 1.

A Graham and A Johnston were directors for the whole of the year and up to the date of this report. A Horwell was appointed on the 17 October 2005 and was a director up to the date of this report.

Directors' interests in shares of the company

According to the Register required to be kept by Section 325 of the Companies Act 1985, none of the directors held any beneficial interest in the shares of the company at 31 January 2006 or 1 February 2005.

Motor Neurone Disease (Sales) Limited

Directors' Report

For the year ended 31 January 2006

Directors' responsibilities

The directors are required by UK company law to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company as at the end of the financial year and of the profit or loss and total recognised gains and losses of the company for that period.


The directors confirm that suitable accounting policies have been used and applied consistently, and reasonable and prudent judgements and estimates have been made in the preparation of the financial statements for the year ended 31 January 2006. The directors also confirm that applicable accounting standards have been followed and the financial statements have been prepared on the going concern basis.

The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the Companies Act 1985. They are also responsible for safeguarding the assets of the company, and for taking reasonable steps to prevent and detect fraud and other irregularities.

Auditors

Sayer Vincent were re-appointed as auditors in the year and have expressed their willingness to continue in that capacity.

By order of the Board



M Watkins
Company Secretary
15 July 2006

Motor Neurone Disease (Sales) Limited

Report of the Independent Auditors to the shareholders of Motor Neurone Disease (Sales) Limited

We have audited the financial statements of Motor Neurone Disease (Sales) Limited for the year ended 31 January 2006 which comprise the profit and loss account, balance sheet and related notes. These financial statements have been prepared in accordance with the accounting policies set out therein.

This report is made solely to the company's shareholders, as a body, in accordance with section 235 of the Companies Act 1985. Our audit work has been undertaken so that we might state to the company's shareholders those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's shareholders as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of the directors and auditors

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Companies Act 1985. We also report to you if, in our opinion, the report of the directors is not consistent with the financial statements, if the company has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding the directors' remuneration and other transactions is not disclosed.

We read the report of the directors and consider the implications for our report if we become aware of any apparent misstatements within it.

Basis of opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the directors in the preparation of financial statements, and of whether the accounting policies are appropriate to the company's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Motor Neurone Disease (Sales) Limited

Report of the Independent Auditors to the shareholders of Motor Neurone Disease (Sales) Limited

Opinion

In our opinion the financial statements:

- give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice, of the state of the company's affairs as at 31 January 2006 and of its results for the year then ended; and
- have been properly prepared in accordance with the Companies Act 1985



SAYER VINCENT

Chartered accountants & registered auditors
London

18 July 2006

Motor Neurone Disease (Sales) Limited

Profit and Loss Account

For the year ended 31 January 2006

	Notes	2006 £	2005 £
Turnover	2	338,652	208,039
Cost of sales		(248,990)	(99,582)
Gross Profit		<u>89,662</u>	<u>108,457</u>
Administration expenses		(6,365)	(6,450)
Gift Aid Donation to parent company		(78,433)	(97,586)
Operating profit	3	<u>4,864</u>	<u>4,421</u>
Interest receivable		1,461	1,872
Interest payable		(1,325)	(1,293)
Result before tax		5,000	5,000
Corporation Tax	5	-	-
Result for the year after tax		<u>5,000</u>	<u>5,000</u>
Retained profits at 1 February 2005		14,255	9,255
Retained profits at 31 January 2006		<u>19,255</u>	<u>14,255</u>

The company has no recognised gains or losses other than those included in the profits or losses above and therefore no separate statement of total recognised gains and losses has been presented. The turnover and profits for 2006 and 2005 are derived totally from continuing operations within the meaning of Financial Reporting Standard 3.

Motor Neurone Disease (Sales) Limited

Balance Sheet

As at 31 January 2006

	Notes	2006 £	2005 £
Current Assets			
Stocks	6	8,446	10,664
Debtors and prepayments	7	51,809	57,945
Cash at bank and in hand		88,109	30,284
		<u>148,364</u>	<u>98,893</u>
Creditors: amounts falling due within one year	8	<u>129,107</u>	<u>84,636</u>
Net assets		<u>19,257</u>	<u>14,257</u>
Capital and reserves			
Called up share capital	9	2	2
Profit and loss account		19,255	14,255
Equity shareholders' funds	10	<u>19,257</u>	<u>14,257</u>

The financial statements on pages 6 to 10 were approved by the Board on 15 July 2006.



A Johnston
Director
15 July 2006

Motor Neurone Disease (Sales) Limited

Notes to the Financial Statements

For the year ended 31 January 2006

1 Principal accounting policies

The financial statements have been prepared in accordance with applicable Accounting Standards in the United Kingdom. A summary of the more important accounting policies, which have been applied consistently, is set out below:

Basis of accounting

The financial statements are prepared in accordance with the historical cost convention.

Turnover

Turnover, which excludes value added tax and trade discounts, represents the invoiced value of goods supplied.

Stocks

Stocks are stated at the lower of cost and net realisable value. In general, cost is determined on a first in first out basis and includes transport and handling costs. Net realisable value is the price at which stocks can be sold in the normal course of business after allowing for the costs of realisation. Provision is made where necessary for obsolete, slow moving and defective stocks.

2 Turnover

The majority of turnover is generated in the United Kingdom; turnover from overseas accounts for less than 1% of the total.

3 Operating profit

Operating profit is stated after charging:

	2006 £	2005 £
Auditors' remuneration – for audit	<u>1,000</u>	<u>1,000</u>

4 Directors' emoluments

No emoluments are paid to any director.

5 Taxation on profits on ordinary activities

	2006 £	2005 £
Corporation tax	<u>-</u>	<u>-</u>

Motor Neurone Disease (Sales) Limited

Notes to the Financial Statements

For the year ended 31 January 2006

6 Stocks

	2006 £	2005 £
Goods for resale	<u>8,446</u>	<u>10,664</u>

7 Debtors and prepayments

	2006 £	2005 £
Trade debtors	25,548	24,568
Other debtors	26,261	33,377
	<u>51,809</u>	<u>57,945</u>

8 Creditors: amounts falling due within one year

	2006 £	2005 £
Trade creditors	5,906	11,557
Loan due to parent company	20,000	20,000
Owed to parent company	89,645	43,889
VAT	9,086	111
Accruals	1,000	1,000
Other creditors	3,470	8,079
	<u>129,107</u>	<u>84,636</u>

9 Share Capital

	2006 £	2005 £
Authorised share capital: 100 ordinary shares of £1 each	<u>100</u>	<u>100</u>
Allotted, called up and fully paid share capital: 2 ordinary shares of £1 each	<u>2</u>	<u>2</u>

Motor Neurone Disease (Sales) Limited

Notes to the Financial Statements

For the year ended 31 January 2006

10 Reconciliation of movements in shareholders' funds

	2006 £	2005 £
Result for the year after tax	5,000	5,000
Opening shareholders' funds	14,257	9,257
Closing shareholders' funds	19,257	14,257

11 Ultimate parent company

The ultimate parent company is Motor Neurone Disease Association, registered office David Niven House, 10-15 Notre Dame Mews, Northampton, NN1 2PR, which is registered in England and Wales.